Phase 3 N=135 Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema
Otic Eczema
Primary: Analysis of the Itching Change at the End of Treatment. — -1.63; -1.25 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=75 OTO-201 for the Treatment of Otitis Externa
Otitis Externa
Primary: Otoscopic Examination: Tympanic Membrane — 6; 8; 8 Participants
Phase 3 N=262 Phase 3 Study of OTO-201 in Acute Otitis Externa
Acute Otitis Externa · Swimmer's Ear
Primary: Number of Subjects Considered a Clinical Cure at Day 8 — 91; 63 Participants
Phase 3 N=118 SVT-15652 Otic Solution for the Treatment of Otomycosis
Otomycosis
Primary: Therapeutical Cure (Clinical and Mycological Cure) — 48; 10 Participants
Phase 3 N=110 SVT-15652 Otic Solution for the Treatment of Otomycosis.
Otomycosis
Primary: Therapeutic Cure (Clinical and Mycological Cure) — 59; 8 Participants
Phase 3 N=693 Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Acute Otitis Externa
Primary: Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit — 71.7; 33.3 percentage of participants
Phase 3 N=549 Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Acute Otitis Externa
Primary: Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit — 68.7; 40.0 Percentage of participants
Phase 3 N=179 Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)
Otomycosis
Primary: Percentage of Subjects With Therapeutic Cure — 14; 11; 53; 53 Participants
Phase 2 N=69 A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis
Acute Otitis Externa
Primary: Adverse Events (AEs) — 10; 3; 6; 1 participants
Phase 3 N=493 Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa
Acute Otitis Externa
Primary: Therapeutic Cure (Clinical + Microbiological Cure) — 63; 49; 20 Participants
Phase 3 N=112 Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis
Otomycosis
Primary: Number of Participants With Clinical Cure — 19; 18 Participants
Phase 3 N=499 Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa
Acute Otitis Externa
Primary: Number of Participants With Clinical Cure of AOE — 190; 191 Participants
Phase 2 N=65 Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis
Otomycosis
Primary: Primary Efficacy Endpoint — 1; 3; 1 Participants
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
N/A N=119 Ear Drops for Children With Otitis Media
Acute Otitis Media
Primary: Resolution of Otitis Media Symptoms — 14.2; 16.5; 7.5; 14.1 units on a scale — p=.002
Phase 3 N=190 Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis
Otomycosis
Primary: Proportion of Subjects With a Complete Response to Treatment — 72; 66; 11; 11 participants
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Phase 2 N=53 Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema
Atopic Dermatitis
Primary: Change From Baseline in the Itch Assessment Score Immediately Following Treatment — 1.93; 2.64 units on a scale — p=<0.001
Phase 3 N=385 Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)
Otitis Media With Effusion in Children · Otitis Media Recurrent
Primary: Percentage of Subjects With Sustained Clinical Cure at Day 8 — 76.2; 71.8; 56.8 percentage of participants
N/A N=90 Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema
Atopic Dermatitis
Primary: Eczema Area and Severity Index (EASI) — 3.014; 3.359; 1.286; 1.621 units on a scale
Phase 3 N=356 Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT) - Study 2
Otitis Media With Effusion in Children · Otitis Media Recurrent
Primary: Percentage of Subjects With Sustained Clinical Cure at Day 8 — 77.1; 75.5; 65.3 percentage of participants
Phase 2 N=95 Dose Ranging Study of OTO-201 in AOMT
Acute Otitis Media · AOMT
Primary: Number of Subjects With Adverse Events — 19; 14; 4 Participants
N/A N=148,166 Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic Dermatitis Eczema · Atopic Dermatitis · Eczema
Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants
N/A N=22 Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto)
Acute Otitis Media · Acute Otitis Externa
Primary: Number of Antibiotic Prescriptions — 140; 115; 6; 7 Emergency department encounters
Phase 3 N=73 OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 1.68; 2.66 units on a scale
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
Phase 3 N=86 OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 2.04; 2.31 units on a scale
Phase 2 N=68 OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching — 1.80; 2.58; 1.72; 2.70 units on a scale (0 -4)
Phase 3 N=793 Study of 0416 Ointment in the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment — 104; 121; 67 participants
Phase 3 N=899 Study of 0417 Ointment in the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment — 123; 130; 86 participants